首页|PDCA循环模式在三级公立医院重点监控药品管理体系中的运用

PDCA循环模式在三级公立医院重点监控药品管理体系中的运用

扫码查看
目的 应用PDCA循环模式对重点监控药品的使用进行管理,为医疗机构重点监控药品质量管理提供借鉴。方法 比较某院采用PDCA法前后重点监控药品的消耗及处方点评情况。对照组为 2019 年传统管理法的住院病例,观察组为 2020 年、2021 年采用PDCA管理法的住院病例,对两组进行统计分析,评估管理效果。结果 实施PDCA循环法管理后,重点监控药品消耗金额大幅下降;适应证不适宜、药品用法用量不适宜、遴选药品不适宜、联合用药不适宜等处方不合理问题得到有效控制,国家重点监控药品金额占比由 2019 年的6%降低至 2020 年的 1。79%,2021 年的 0。17%;处方合格率持续升高。结论 PDCA循环管理法针对重点监控药品持续闭环管理,明显控制药费,减轻患者经济负担,促进合理用药,降低不良反应发生率,保证医疗质量。
The application of PDCA cycle mode in the key monitoring drug management system of a tertiary public hospital
Objective To apply the PDCA cycle model to manage the use of key monitored drugs,and to provide a reference for the quality management of key monitored drugs in medical institutions.Methods Compared the consumption and prescription reviews of key monitored drugs before and after adopting the PDCA method in a hospital.The control group was the hospitalized cases with the traditional management method in 2019,and the observation group was the hospitalized cases with the PDCA management method in 2020 and 2021.Results After the implementation of PDCA cycle management,the consumption amount of key monitored drugs decreased sharply.Unreasonable prescription problems such as inappropriate indications,inappropriate dosage of drugs,inappropriate selected drugs,and inappropriate combination drugs have been effectively controlled,and the proportion of national key monitored drugs decreased from 6%in 2019 to 1.79%in 2020 and 0.17%in 2021;The prescription pass rate continued to increase.Conclusion The PDCA cycle management method is aimed at the continuous closed-loop management of key monitored drugs,which can significantly control the drug cost of patients,reduce the economic burden of patients,promote rational drug use,reduce the incidence of adverse reactions,and ensure the quality of medical care.

Key monitoring drugsPDCA cycle management methodRational use of medicines

孔敏、姚瑛、陈雯、王昊、吴文利、景晶、陆钊罡、高圆、王基云、王健

展开 >

宁夏回族自治区人民医院药学部,银川 750002

重点监控药品 PDCA循环管理法 合理用药

2024

中国处方药
南方医药经济研究所

中国处方药

影响因子:0.649
ISSN:1671-945X
年,卷(期):2024.22(7)